MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies

 MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies

MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies

Shots:

  • MSD enters into a research collaboration and exclusive license agreement for the discovery and development of undisclosed vaccine candidates utilizing Themis’ measles virus vector-based platform
  • Themis to receive ~200M development and commercial milestones and royalties on approved products from the agreement. MSD to provide research funding and make an equity investment in Themis
  • Themis licenses its measles virus vector-based platform from the Pasteur Institute in Paris, incorporating large recombinant genes coding for selected antigens into its genome

Click here to­ read full press release/ article | Ref: Themis Bioscience | Image: Guide-Post Solutions

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post